KL003 cell injection Drug Product

GENETIC3 trials

Sponsors

Institute of Hematology & Blood Diseases Hospital, China, Kanglin Biotechnology (Hangzhou) Co., Ltd.

Conditions

Transfusion-dependent Beta-Thalassemia

Phase 1

Β-Thalassemia Treatment with KL003 Cell Injection

RecruitingNCT06280378

Kanglin Biotechnology (Hangzhou) Co., Ltd.Transfusion-dependent Beta-Thalassemia

Start: 2024-04-05End: 2027-05-31Target: 41Updated: 2025-03-10

Unknown Phase

Evaluation the Safety and Efficacy of KL003 Cell Injection in the Treatment of Transfusion-dependent β-thalassemia.

Active, not recruitingNCT05860595

Institute of Hematology & Blood Diseases Hospital, ChinaTransfusion-dependent Beta-Thalassemia

Start: 2023-05-23End: 2025-10-24Target: 3Updated: 2025-08-05

Safety and Efficacy of the Lentiviral Vector in Gene Therapy of Beta-thalassemia Patients

RecruitingNCT06219239

Institute of Hematology & Blood Diseases Hospital, ChinaTransfusion-dependent Beta-Thalassemia

Start: 2024-01-04End: 2026-12-31Target: 3Updated: 2025-08-05

Related Papers

Deciphering Hematopoietic Reconstitution Dynamics of Lentiviral Vector HBBT87Q-Engineered Hematopoietic Stem Cells Gene Therapy for β-Thalassemia Patients

Blood2024-11-05